Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works

Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · see citing works

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,684 · see citing works

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733 · see citing works

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,319 · see citing works

Interpreting the significance of changes in health-related quality-of-life scores.

Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,971 · see citing works

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503 · see citing works

Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater

Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670 · see citing works

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenégre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z. G., Geater, S. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,667 · see citing works

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30167-6 · Cited by 1,662 · see citing works

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Migden, M. R., Rischin, D., Schmults, C. D., Guminski, A. D., Hauschild, A., Lewis, K. D., Chung, C. H., Hernandez-Aya, L. F., Lim, A. M. L., Chang, A. L. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805131 · Cited by 1,427 · see citing works

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Chirieac, L. R., D’Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M. C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,305 · see citing works

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger‐Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D. A., Vennapusa, B., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,277 · see citing works

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

Rimm, D. L., Han, G., Taube, J. M., Yi, E. S., Bridge, J. A., Flieder, D. B., Homer, R., West, W. W., Wu, H., Roden, A. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0013 · Cited by 764 · see citing works

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Hanna, N. H., Schneider, B. J., Temin, S., Baker, S., Brahmer, J. R., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03022 · Cited by 463 · see citing works

Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice

Murphy, A. J., Macdonald, L. E., Stevens, S. G., Karow, M. L., Dore, A. T., Pobursky, K. J., Huang, T. T., Poueymirou, W. T., Esau, L., Meola, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324022111 · Cited by 457 · see citing works

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

Migden, M., Khushalani, N., Chang, A., Lewis, K., Schmults, C., Hernandez-Aya, L., Meier, F., Schadendorf, D., Guminski, A., Hauschild, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30728-4 · Cited by 423 · see citing works

Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes

Macdonald, L. E., Karow, M. L., Stevens, S. G., Auerbach, W., Poueymirou, W. T., Yasenchak, J., Frendewey, D. A., Valenzuela, D. M., Giallourakis, C. C., Alt, F. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323896111 · Cited by 392 · see citing works

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

Rischin, D., Migden, M. R., Lim, A. M. L., Schmults, C. D., Khushalani, N. I., Hughes, B. G. M., Schadendorf, D., Dunn, L. A., Hernandez-Aya, L. F., Chang, A. L. S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000775 · Cited by 178 · see citing works

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Pilkington, G., Boland, A., Brown, T. J., Oyee, J., Bagust, A., & Dickson, R. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-205914 · Cited by 117 · see citing works

Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice

Burova, E., Hermann, A., Waite, J. C., Potocky, T. B., Lai, V. K.-M., Hong, S., Liu, M., Allbritton, O., Woodruff, A., Wu, Q., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0665 · Cited by 115 · see citing works

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Papadopoulos, K. P., Johnson, M. L., Lockhart, A. C., Moore, K., Falchook, G. S., Formenti, S. C., Naing, A., Carvajal, R. D., Rosen, L. S., Weiss, G. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2609 · Cited by 66 · see citing works

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials

Scagliotti, G. V., Gridelli, C., de Marinis, F., Thomas, M., Dediu, M., Pujol, J.-L., Manegold, C., Antonio, B. S., Peterson, P. M., John, W. J., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.07.005 · Cited by 24 · see citing works

Lung Cancer in Women, a Different Disease: Survival Differences by Sex in Turkey

Ulaş, A., Tokluoğlu, S., Köş, M., Sılay, K., Akıncı, S., Öksüzoğlu, B. Ç., & Alkış, N. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.2.815 · Cited by 22 · see citing works

Immunotherapy in treatment naïve advanced non-small cell lung cancer

Ernani, V., & Ganti, A. K. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.94 · Cited by 17 · see citing works

Frontline immunotherapy for NSCLC: alone or not alone?

Gridelli, C., & Casaluce, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0070-7 · Cited by 11 · see citing works

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from phase 1 dose escalation and NSCLC Expansion Cohort.

Moreno, V., Calvo, E., Garcia, M. E. O., Gil-Martín, M., Aljumaily, R. M., Papadopoulos, K. P., Rosen, L. S., Rietschel, P., Mohan, K. K., Li, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e21057 · Cited by 5 · see citing works

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from a phase I dose escalation and NSCLC expansion cohort.

Moreno, V., Calvo, E., Garcia, M. E. O., Gil-Martín, M., Aljumaily, R. M., Papadopoulos, K. P., Rosen, L. S., Rietschel, P., Mohan, K. K., Li, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.8_suppl.116 · Cited by 5 · see citing works

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015

Nicholson, A. G., Tsao, M., Beasley, M. B., Borczuk, A., Brambilla, E. M., Cooper, W. A., Đačić, S., Jain, D., Kerr, K. M., Lantuéjoul, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,606 · see citing works

Immune Checkpoint Inhibitors in Cancer Therapy

Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353 · see citing works

Toward personalized treatment approaches for non-small-cell lung cancer

Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,113 · see citing works

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

Passaro, A., Bakir, M. A., Hamilton, E. G., Diehn, M., André, F., Roy‐Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 703 · see citing works

Non-small-cell lung cancer

Hendriks, L. E. L., Remón, J., Finn, C. F., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 672 · see citing works

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Hendriks, L. E. L., Kerr, K. M., Menis, J., Mok, T. S. K., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 644 · see citing works

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Socinski, M. A., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez‐Abreu, D., Moro‐Sibilot, D., Thomas, C. A., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.009 · Cited by 539 · see citing works

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons

Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L. P., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 526 · see citing works

Survival with Cemiplimab in Recurrent Cervical Cancer

Tewari, K. S., Monk, B. J., Vergote, I., Miller, A., de Melo, A. C., Kim, H.-S., Kim, Y. M., Lisyanskaya, A., Samouëlian, V., Lorusso, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112187 · Cited by 474 · see citing works

Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study

Johnson, M. L., Cho, B. C., Luft, A., Alatorre-Alexander, J., Geater, S. L., Laktionov, K., Kim, S.-W., Ursol, G., Hussein, M., Lim, F. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00975 · Cited by 463 · see citing works

Advances in systemic therapy for non-small cell lung cancer

Miller, M., & Hanna, N. H. (2021) · BMJ · doi:10.1136/bmj.n2363 · Cited by 384 · see citing works

Immunotherapy in Lung Cancer: Current Landscape and Future Directions

Mamdani, H. M., Matosevic, S., Khalid, A. B., Durm, G. A., & Jalal, S. I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.823618 · Cited by 370 · see citing works

Recent advances in non-small cell lung cancer targeted therapy; an update review

Araghi, M., Mannani, R., Maleki, A. H., Hamidi, A., Rostami, S. M., Safa, S. H., Faramarzi, F., Khorasani, S., Alimohammadi, M., Tahmasebi, S., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02990-y · Cited by 352 · see citing works

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Ren, S., Chen, J., Xu, X., Jiang, T., Cheng, Y., Chen, G., Pan, Y., Fang, Y., Wang, Q., Huang, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.018 · Cited by 324 · see citing works

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Gogishvili, M., Melkadze, T., Makharadze, T., Giorgadze, D., Dvorkin, M. V., Penkov, K., Лактионов, К. К., Nemsadze, G., Nechaeva, M., Rozhkova, I., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01977-y · Cited by 319 · see citing works

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

Stratigos, A., Sekulić, A., Peris, K., Bechter, O. E., Prey, S., Kaatz, M., Lewis, K. D., Basset‐Séguin, N., Chang, A. L. S., Dalle, S., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00126-1 · Cited by 294 · see citing works

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier

Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 278 · see citing works

Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Mithoowani, H., & Febbraro, M. (2022) · Current Oncology · doi:10.3390/curroncol29030150 · Cited by 272 · see citing works

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade

Genova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., Gangemi, R. M. R., Filaci, G., Coco, S., & Croce, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799455 · Cited by 265 · see citing works

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

Tang, S., Qin, C., Hu, H., Liu, T., He, Y., Guo, H., Yan, H., Zhang, J., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11030320 · Cited by 262 · see citing works

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC

Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00520-1 · Cited by 252 · see citing works

Hot and cold tumors: Immunological features and the therapeutic strategies

Wang, L., Geng, H., Liu, Y., Liu, L., Chen, Y., Wu, F., Liu, Z., Ling, S., Wang, Y., & Zhou, L. (2023) · MedComm · doi:10.1002/mco2.343 · Cited by 246 · see citing works

Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy

Rodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 237 · see citing works

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

Reckamp, K. L., Redman, M. W., Dragnev, K. H., Minichiello, K., Villaruz, L. C., Faller, B. A., Baghdadi, T. A., Hines, S. J., Everhart, L., Highleyman, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00912 · Cited by 237 · see citing works

Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee

Mino-Kenudson, M. A., Schalper, K. A., Cooper, W. A., Đačić, S., Hirsch, F. R., Jain, D., López‐Ríos, F., Tsao, M., Yatabe, Y., Beasley, M. B., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.109 · Cited by 231 · see citing works

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Jassem, J., de Marinis, F., Giaccone, G., Vergnenégre, A., Barrios, C. H., Morise, M., Felip, E., Oprean, C. M., Kim, Y., Andric, Z. G., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.019 · Cited by 215 · see citing works

Immune Checkpoint Inhibitor Therapy in Oncology

Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.004 · Cited by 215 · see citing works

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities

Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210 · see citing works

Update 2025: Management of Non‑Small-Cell Lung Cancer

Jeon, H., Wang, S., Song, J., Gill, H., & Cheng, H. (2025) · Lung · doi:10.1007/s00408-025-00801-x · Cited by 210 · see citing works

Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

Mountzios, G., Remón, J., Hendriks, L. E. L., García‐Campelo, R., Rolfo, C. D., Schil, P. E. V., Forde, P. M., Besse, B., Subbiah, V., Reck, M., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00794-7 · Cited by 204 · see citing works

Advances in molecular pathology and therapy of non-small cell lung cancer

Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197 · see citing works

A comprehensive review of immune checkpoint inhibitors for cancer treatment

Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 196 · see citing works

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors

Cook, S., Samuel, V., Meyers, D. E., Stukalin, I., Litt, I., Sangha, R. S., Morris, D. G., Heng, D. Y. C., Pabani, A., Dean, M. L., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.52302 · Cited by 178 · see citing works

Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy

Lee, J. B., Kim, H. R., & Ha, S. (2022) · Immune Network · doi:10.4110/in.2022.22.e2 · Cited by 173 · see citing works

Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials

Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 172 · see citing works

Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis

Santoni, M., Rizzo, A., Kucharz, J., Mollica, V., Rosellini, M., Marchetti, A., Tassinari, E., Monteiro, F. S. M., Soares, A., Molina‐Cerrillo, J., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03349-4 · Cited by 150 · see citing works

Immunotherapy for Advanced Non–Small Cell Lung Cancer: A Decade of Progress

Shields, M. D., Marin-Acevedo, J. A., & Pellini, B. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321483 · Cited by 141 · see citing works

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations

Dantoing, E., Piton, N., Salaün, M., Thiberville, L., & Guisier, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126288 · Cited by 142 · see citing works

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline

Singh, N., Temin, S., Baker, S., Blanchard, E. M., Brahmer, J. R., Celano, P., Duma, N., Ellis, P. M., Elkins, I. B., Haddad, R. Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00825 · Cited by 132 · see citing works

Increasing cure rates of solid tumors by immune checkpoint inhibitors

Ma, W., Xue, R., Zhu, Z. G., Farrukh, H., Song, W., Li, T., Zheng, L., & Pan, C.-X. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00372-8 · Cited by 128 · see citing works

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 125 · see citing works

Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives

Guo, H., Zhang, J., Qin, C., Yan, H., Liu, T., Hu, H., Tang, S., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11203200 · Cited by 118 · see citing works

Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

de Miguel‐Pérez, D., Russo, A., Arrieta, O. G., Ak, M., Barrón, F., Gunasekaran, M., Mamindla, P., Lara‐Mejía, L., Peterson, C. B., Er, M. E., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02379-1 · Cited by 117 · see citing works

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

Makharadze, T., Gogishvili, M., Melkadze, T., Baramidze, A., Giorgadze, D., Penkov, K., Лактионов, К. К., Nemsadze, G., Nechaeva, M., Rozhkova, I., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.03.008 · Cited by 114 · see citing works

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

Özgüroğlu, M., Kılıçkap, S., Sezer, A., Gümüş, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Çiçin, İ., Ho, G. F., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00329-7 · Cited by 112 · see citing works

Emerging evidence and treatment paradigm of non-small cell lung cancer

Liu, S. M., Zheng, M.-M., Pan, Y., Liu, S. M., Li, Y., & Wu, Y.-L. L. C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01436-2 · Cited by 105 · see citing works

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Paz-Ares, L. G., Ciuleanu, T., Cobo, M., Bennouna, J., Schenker, M., Cheng, Y., Juan, Ó., Mizutani, H., Lingua, A., Reyes-Cosmelli, F., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.10.014 · Cited by 104 · see citing works

Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

Cho, B. C., Lee, J. S., Wu, Y.-L. L. C., Çiçin, İ., Cobo, M., Ahn, M., Cuppens, K., Veillon, R., Nadal, E., Dias, J. M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.08.018 · Cited by 104 · see citing works

Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data

Pérol, M., Felip, E., Dafni, U. G., Polito, L., Pal, N., Tsourti, Z., Ton, T. G. N., Merritt, D., Morris, S., Stahel, R. A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.008 · Cited by 103 · see citing works

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC

Alessi, J. V., Elkrief, A., Ricciuti, B., Wang, X., Cortellini, A., Vaz, V. R., Lamberti, G., Frias, R. L., Venkatraman, D., Fulgenzi, C. A. M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.091 · Cited by 97 · see citing works

Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism

Yin, J., Wu, Y., Yang, X., Gan, L., & Xue, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830631 · Cited by 95 · see citing works

Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials

Conforti, F., Pala, L., Pagan, E., Corti, C., Bagnardi, V., Queirolo, P., Catania, C., Pas, T. M. D., & Giaccone, G. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100251 · Cited by 92 · see citing works

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer

Ghiringhelli, F., Bibeau, F., Greillier, L., Fumet, J.-D., Ilie, A., Monville, F., Laugé, C., Catteau, A., Boquet, I., Majdi, A., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104633 · Cited by 91 · see citing works

Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial

Schüler, M., Cuppens, K., Plönes, T., Wiesweg, M., Pont, B. D., Hegedűs, B., Köster, J., Mairinger, F. D., Darwiche, K., Paschen, A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02965-0 · Cited by 90 · see citing works

Immunotherapy in non-small cell lung cancer: Past, present, and future directions

Punekar, S. R., Shum, E., Grello, C., Lau, S. C. M., & Velcheti, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877594 · Cited by 88 · see citing works

Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3

Jaiyesimi, I. A., Leighl, N. B., Ismaila, N., Alluri, K. C., Florez, N., Gadgeel, S. M., Masters, G. A., Schenk, E. L., Schneider, B. J., Sequist, L. V. D., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02746 · Cited by 87 · see citing works

PD-L1: expression regulation

Zhou, Y.-J., Li, G., Wang, J., Liu, M., Wang, Z., Song, Y., Zhang, X., & Wang, X. (2023) · Blood Science · doi:10.1097/bs9.0000000000000149 · Cited by 85 · see citing works

Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study

Yang, Z., Gao, J., Zheng, J., Han, J., Li, A., Liu, G., Sun, Y., Zhang, J., Chen, G., Xu, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01762-y · Cited by 85 · see citing works

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1–High NSCLC

Akinboro, O., Larkins, E., Pai-Scherf, L. H., Mathieu, L. N., Ren, Y., Cheng, J., Fiero, M. H., Fu, W., Bi, Y., Kalavar, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3844 · Cited by 84 · see citing works

Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases

Zhang, M., Fan, Y., Nie, L., Wang, G., Sun, K., & Cheng, Y. (2022) · CHEST Journal · doi:10.1016/j.chest.2021.12.656 · Cited by 82 · see citing works

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives

Liu, Z., Zhu, Y., Xie, H., & Zou, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1077468 · Cited by 81 · see citing works

Gut commensal Bifidobacterium-derived extracellular vesicles modulate the therapeutic effects of anti-PD-1 in lung cancer

Preet, R., Islam, M. A., Shim, J., Rajendran, G., Mitra, A., Vishwakarma, V., Kutz, C., Choudhury, S., Pathak, H. B., Dai, Q., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58553-4 · Cited by 81 · see citing works

The emerging roles of NGS in clinical oncology and personalized medicine

Hussen, B. M., Abdullah, S. T., Salihi, A. B., Sabir, D. K., Sidiq, K. R., Rasul, M. F., Hidayat, H. J., Ghafouri‐Fard, S., Taheri, M. N., & Jamali, E. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153760 · Cited by 80 · see citing works

Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations

Chen, X., Chen, L., Peng, X., Deng, L., Wang, Y., Li, J.-J., Guo, D., & Niu, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101851 · Cited by 80 · see citing works

Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial

Zhou, C., Chen, G., Huang, Y., Zhou, J., Lin, L., Feng, J., Wang, Z., Shu, Y., Shi, J., Hu, Y., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.12.017 · Cited by 75 · see citing works

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Ready, N., Audigier-Valette, C., Goldman, J. W., Felip, E., Ciuleanu, T., Campelo, M. R. G., Jao, K., Barlési, F., Bordenave, S., Rijavec, E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006127 · Cited by 75 · see citing works

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

Yang, F., Shay, C., Abousaud, M. I., Tang, C., Li, Y., Qin, Z. S., Saba, N. F., & Teng, Y. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02568-y · Cited by 74 · see citing works

Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review

Larroquette, M., Domblides, C., Lefort, F., Lasserre, M., Quivy, A., Sionneau, B., Bertolaso, P., Gross‐Goupil, M., Ravaud, A., & Daste, A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.013 · Cited by 73 · see citing works

Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT)

Ohri, N., Jolly, S., Cooper, B. T., Kabarriti, R., Bodner, W. R., Klein, J., Guha, C., Shankar, V., Shum, E., Sabari, J. K., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00627 · Cited by 70 · see citing works

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges

Yang, F., Wang, J., Wang, Y., Liu, B., & Molina, J. R. (2021) · Cancers · doi:10.3390/cancers14010109 · Cited by 69 · see citing works

A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC

Wang, L., Luo, Y., Ren, S., Zhang, Z., Xiong, A., Su, C., Zhou, J., Yu, X., Hu, Y., Zhang, X., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.014 · Cited by 67 · see citing works

Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review

Olivares-Hernández, A., Portillo, E. G.-D., Tamayo-Velasco, Á., Figuero-Pérez, L., Zhilina-Zhilina, S., Fonseca‐Sánchez, E., & Miramontes‐González, J. P. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4218 · Cited by 66 · see citing works

CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

Neal, J. W., Pavlakis, N., Kim, S., Goto, Y., Lim, S. M., Mountzios, G., Fountzilas, E., Mochalova, A. S., Christoph, D. C., Bearz, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02166 · Cited by 65 · see citing works

Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions

Wang, Y., Safi, M., Hirsch, F. R., Lu, S., Peters, S., Govindan, R., Rosell, R., Park, K., & Zhang, J. J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00979-8 · Cited by 65 · see citing works

Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance

Deng, J., Zhou, M. L., Liao, T., Kuang, W., Xia, H., Yin, Z., Tan, Q., Li, Y., Song, S., Zhou, E., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818453 · Cited by 63 · see citing works

Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects

Peters, S., Paz-Ares, L. G., Herbst, R. S., & Reck, M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004863 · Cited by 60 · see citing works

Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review

Li, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 60 · see citing works

The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis

Chu, X., Niu, L., Xiao, G., Peng, H., Deng, F., Liu, Z., Wu, H., Yang, L., Tan, Z., Li, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.875488 · Cited by 57 · see citing works

Clinical development of immuno-oncology therapeutics

Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 57 · see citing works

Treatment of NSCLC after chemoimmunotherapy — are we making headway?

Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 56 · see citing works

Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents

Singh, T., Hassanabad, M. F., & Hassanabad, A. F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188636 · Cited by 54 · see citing works

Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy

Lee, C. K., Atibalentja, D. F., Yao, L. E., Park, J., Kuruvilla, S. P., & Felsher, D. W. (2022) · Nanotheranostics · doi:10.7150/ntno.65544 · Cited by 53 · see citing works

Immunosenescence, inflammaging, and cancer immunotherapy efficacy

Rodriguez, J. E., Naigeon, M., Goldschmidt, V., Dugage, M. R., Seknazi, L., Danlos, F., Champiat, S., Marabelle, A., Michot, J., Massard, C., et al. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2098718 · Cited by 53 · see citing works

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors

Teng, Y.-S., & Yu, S. (2023) · Current Oncology · doi:10.3390/curroncol30070498 · Cited by 53 · see citing works

Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies

Michielin, O. A., Lalani, A. A., Robert, C., Sharma, P., & Peters, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003024 · Cited by 52 · see citing works

Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer

Bischoff, P., Reck, M., Overbeck, T. R., Christopoulos, P., Rittmeyer, A., Lüders, H., Kollmeier, J., Kulhavy, J., Kemper, M., Reinmuth, N., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.12.015 · Cited by 52 · see citing works

Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial

Wang, J., Lu, S., Yu, X., Hu, Y., Zhao, J., Sun, M., Yu, Y., Hu, C., Yang, K., Song, Y., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103727 · Cited by 52 · see citing works

Immunotherapy of Lung Cancer

Rybkin, I. I., & Gadgeel, S. M. (2022) · Medical radiology · doi:10.1007/174_2022_313 · Cited by 51 · see citing works

Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy

Fan, S., Jiang, Z., Zhang, Z., Xing, J., Wang, D., & Tang, D. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05199-8 · Cited by 50 · see citing works

Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta‐Analysis of Observational Studies and Randomized Controlled Trials

Sharma, A., Alexander, G., Chu, J. H., Markopoulos, A., Maloul, G., Ayub, M. T., Fidler, M. J., & Okwuosa, T. M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032620 · Cited by 49 · see citing works

The Role of the Tumor Microenvironment (TME) in Advancing Cancer Therapies: Immune System Interactions, Tumor-Infiltrating Lymphocytes (TILs), and the Role of Exosomes and Inflammasomes

Erasha, A. M., El-Gendy, H. F., Aly, A. S., Fernández‐Ortiz, M., & Sayed, R. K. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062716 · Cited by 49 · see citing works

What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?

Wang, Q., Xie, B., Liu, S., Shi, Y., Tao, Y., Xiao, D., & Wang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773168 · Cited by 47 · see citing works

Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung

Santos, E. S., & Rodríguez, E. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.06.002 · Cited by 46 · see citing works

Cancer Immunotherapy and Delivery System: An Update

Yang, M. J., Olaoba, O. T., Zhang, C., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081630 · Cited by 46 · see citing works

Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study

Liu, S., Dong, S., Yang, X., Liao, R.-Q., Jiang, B., Wang, Q., Ben, X., Qiao, G., Lin, J., Yan, H., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01700-4 · Cited by 46 · see citing works

Biomarkers for immunotherapy resistance in non-small cell lung cancer

Rother, C., John, T., & Wong, A. N. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1489977 · Cited by 46 · see citing works

Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis

Liu, S., Gao, W., Ning, Y., Zou, X., Zhang, W., Zeng, L., & Liu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908173 · Cited by 46 · see citing works

Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

Arasanz, H., Bocanegra, A., Morilla, I., Fernández‐Irigoyen, J., Martínez-Aguillo, M., Teijeira, L., Garnica, M., Blanco, E., Chocarro, L., Ausín, K., et al. (2022) · Cancers · doi:10.3390/cancers14163846 · Cited by 44 · see citing works

Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis

Wang, Y., Han, H., Zhang, F., Lv, T., Zhan, P., Ye, M., Song, Y., & Liu, H. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01832-4 · Cited by 44 · see citing works

Immunotherapy in NSCLC Patients with Brain Metastases

Buriolla, S., Pelizzari, G., Corvaja, C., Alberti, M., Targato, G., Bortolot, M., Torresan, S., Cortiula, F., Fasola, G., & Follador, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137068 · Cited by 44 · see citing works

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

Özgüroğlu, M., Kılıçkap, S., Sezer, A., Gümüş, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Çiçin, İ., Ho, G. F., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00329-7 · Cited by 112 · see citing works

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Gogishvili, M., Melkadze, T., Makharadze, T., Giorgadze, D., Dvorkin, M. V., Penkov, K., Лактионов, К. К., Nemsadze, G., Nechaeva, M., Rozhkova, I., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01977-y · Cited by 319 · see citing works

Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1

Kılıçkap, S., Baramidze, A., Sezer, A., Özgüroğlu, M., Gumus, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Çiçin, İ., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.03.033 · Cited by 39 · see citing works

119TiP An observational study to assess the effectiveness and safety of cemiplimab in patients with advanced non-small cell lung cancer (NSCLC) in routine clinical practice within Europe (CEMI-LUNG)

Gessner, C., Griesinger, F., Shah, R., Talbot, T., Venkateshan, S., Shankar, A. K. V., Seluzhytsky, A., & Marsden, D. M. (2022) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2022.100223 · Cited by 3 · see citing works

P2.06-10 Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1

Gümüs, M., Kılıçkap, S., Sezer, A., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., He, X., Gullo, G., Rietschel, P., & Quek, R. G. W. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.556